article thumbnail

STAT+: With a potent new medicine, Merck marks a return to cardiology

STAT News

NEW ORLEANS — A new medicine represents a dramatic advance for patients with a rare condition called pulmonary arterial hypertension — and a return to heart disease for Merck, which long had a legendary presence in cardiology. Continue to STAT+ to read the full story…

article thumbnail

UK regulator backs Amarin’s cardiology drug Vazkepa

pharmaphorum

Amarin’s Vazkepa cardiology drug has been backed by the UK’s drugs regulator, following approval in Europe at the end of March. . The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Calcium channel inhibition promotes cardiac regeneration, offering hope for heart failure treatment

Medical Xpress

Published in npj Regenerative Medicine, the study reveals a novel approach to promoting cardiomyocyte proliferation. DeBakey Department of Surgery at Baylor College of Medicine, the QIMR Berghofer Medical Research Institute in Brisbane, Australia, and collaborating institutions. The researchers are from the Michael E.

Medicine 129
article thumbnail

AGEPHA Pharma’s LODOCO gets US FDA approval for cardiovascular disease

Pharmaceutical Technology

It can be used as a monotherapy or along with cholesterol-lowering medicines. Participants treated with LODOCO had a 31% reduction in the overall risk of cardiovascular death, spontaneous myocardial infarction or ischaemic stroke when added to statins and other cardiology prevention therapies, compared to those treated with placebo.

article thumbnail

July 24, 2024: In This Week’s PCT Grand Rounds, Fonarow to Discuss Interventions for Optimizing Guideline-Directed Medical Therapy

Rethinking Clinical Trials

Fonarow is the Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA, director of the Ahmanson-UCLA Cardiomyopathy Center, and codirector of the UCLA Preventative Cardiology Program. .” The Grand Rounds session will be held on Friday, July 26, 2024, at 1:00 pm eastern. Join the online meeting.

article thumbnail

Integrating Bioanalytical Automation, Biomarkers, Pharmacogenomics, & Cost-Effective Strategies

Worldwide Clinical Trials

Technological advancements have fostered novel drugs and improved precision medicine, suggesting an increased trend of R&D in this direction. We support efficacy markers, safety biomarkers, diagnostic biomarkers, and pharmacodynamic (PD) markers, addressing diverse therapeutic areas such as neurology, oncology, immunology, and cardiology.

article thumbnail

July 12, 2023: In This Week’s PCT Grand Rounds, Lessons From the COORDINATE-Diabetes Trial

Rethinking Clinical Trials

Fortin, MD, Distinguished Professor of Medicine and a professor of nursing, and Dr. Pagidipati is an associate professor of medicine—both at Duke University. Neha Pagidipati In this Friday’s PCT Grand Rounds, Christopher Granger and Neha Pagidipati of Duke University will present “Lessons From the COORDINATE-Diabetes Trial.”

Trials 130